









Markets
/
Stocks
/
nasdaq-achv
/

Achieve Life Sciences Inc

ACHV

4.250USD

+0.300+7.59%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

224.45MMarket Cap

LossP/E TTM



Achieve Life Sciences Inc

4.250

+0.300+7.59%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Achieve Life Sciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Achieve Life Sciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 116 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.38.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Achieve Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

116 / 392

Overall Ranking

250 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Achieve Life Sciences Inc Highlights

StrengthsRisks

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Fairly Valued

The company’s latest PE is -3.13, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 23.50M shares, increasing 0.53% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.47M shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.375

Target Price

+289.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Achieve Life Sciences Inc is 7.02, ranking 167 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Achieve Life Sciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Achieve Life Sciences Inc is 6.16, ranking 322 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.13, which is -80.10% below the recent high of -0.62 and -52.70% above the recent low of -4.78.

Score

Industry at a Glance

Previous score

6.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 116/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Achieve Life Sciences Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.375

Target Price

+289.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Achieve Life Sciences Inc

ACHV

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Achieve Life Sciences Inc is 6.69, ranking 191 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.55 and the support level at 3.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.43

Change

0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.266

Sell

RSI(14)

39.873

Neutral

STOCH(KDJ)(9,3,3)

17.349

Neutral

ATR(14)

0.339

Low Volatility

CCI(14)

-68.568

Neutral

Williams %R

81.215

Oversold

TRIX(12,20)

-0.640

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

4.180

Buy

MA10

4.348

Sell

MA20

4.964

Sell

MA50

4.796

Sell

MA100

4.371

Sell

MA200

3.615

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Achieve Life Sciences Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 57.38%, representing a quarter-over-quarter decrease of 4.99%. The largest institutional shareholder is The Vanguard, holding a total of 2.47M shares, representing 4.65% of shares outstanding, with 6.11% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Simplify Asset Management Inc

4.97M

-32.25%

Franklin Advisers, Inc.

4.46M

The Vanguard Group, Inc.

Star Investors

2.46M

+14.51%

Contrarian Alpha Management, L.L.C.

1.67M

+8.10%

Patrick (Callahan J. III)

1.53M

Marshall Wace LLP

774.85K

Nantahala Capital Management, LLC

648.88K

-27.81%

Two Sigma Investments, LP

549.36K

Geode Capital Management, L.L.C.

506.98K

+39.97%

Pathstone

502.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Achieve Life Sciences Inc is 3.06, ranking 173 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.84. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.